Abstract
FP-DTBZ is a marker of the vesicular monoamine transporter type-2 (VMAT2) and is used in evaluation of Parkinson’s disease.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Further Reading
Lin KJ, Lin WY, Hsieh CJ, et al. Optimal scanning time window for 18F-FP-(+)-DTBZ (18F-AV-133) summed uptake measurements. Nucl Med Biol. 2011;38:1149–55.
Lin KJ, Weng YH, Hsieh CJ, et al. Brain imaging of vesicular monoamine transporter type 2 in healthy aging subjects by 18F-FP-(+)-DTBZ PET. PLoS One. 2013;8:e75952.
Lin KJ, Weng YH, Wey SP, et al. Whole-body biodistribution and radiation dosimetry of 18F-FP-(+)-DTBZ (18F-AV-133): a novel vesicular monoamine transporter 2 imaging agent. J Nucl Med. 2010;51:1480–5.
Zhao C, Liu C, Tang J, et al. An efficient automated radiosynthesis and bioactivity confirmation of VMAT2 tracer [18F]FP-(+)-DTBZ. Mol Imaging Biol. 2020;22:265–73.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Ballinger, J.R. (2022). 18F-FP-DTBZ. In: PET Radiopharmaceuticals. Clinicians’ Guides to Radionuclide Hybrid Imaging(). Springer, Cham. https://doi.org/10.1007/978-3-031-10271-4_51
Download citation
DOI: https://doi.org/10.1007/978-3-031-10271-4_51
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-031-10270-7
Online ISBN: 978-3-031-10271-4
eBook Packages: MedicineMedicine (R0)